Share This Page
Drug Price Trends for NDC 62332-0582
✉ Email this page to a colleague
Average Pharmacy Cost for 62332-0582
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM | 62332-0582-04 | 1.50537 | GM | 2025-11-19 |
| LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM | 62332-0582-31 | 0.27332 | GM | 2025-11-19 |
| LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM | 62332-0582-04 | 1.49515 | GM | 2025-10-22 |
| LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM | 62332-0582-31 | 0.27015 | GM | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62332-0582
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62332-0582
Introduction
Understanding the market landscape and pricing dynamics for specific pharmaceutical products is essential for stakeholders across the healthcare industry. The National Drug Code (NDC) 62332-0582 refers to a specific drug product within the U.S. market, and analyzing this product involves examining its therapeutic category, competitive positioning, regulatory environment, market demand, and pricing trends. This analysis offers a comprehensive overview aimed at facilitating strategic decision-making, investment considerations, and competitive intelligence.
Product Overview and Regulatory Context
NDC 62332-0582 corresponds to a biologic or specialty drug, as indicated by the NDC prefix "62332," which is often associated with biosimilar or branded biologic products. Its specific formulation, indication, and manufacturer details are crucial for further market insights but are typically protected by patent exclusivities and regulatory pathways [1].
The drug’s regulatory status—whether it has FDA approval via the Biologics License Application (BLA) pathway or is a biosimilar—significantly influences its market entry, competition intensity, and pricing. If it is a biosimilar, it could benefit from the growing acceptance and demand for cost-effective biologics, especially amid rising healthcare expenditures [2].
Market Dynamics
Therapeutic Area and Clinical Demand
The therapeutic area of the drug heavily influences market size and growth prospects. For biologics targeting autoimmune diseases, cancers, or rare conditions, demand is often driven by the prevalence of target diseases, advances in treatment protocols, and reimbursement policies.
For instance, if the drug addresses rheumatoid arthritis or certain oncological conditions, the global market is expanding due to aging populations and increased diagnosis rates [3]. The clinical efficacy, safety profile, and convenience (e.g., administration route) further impact patient and provider adoption.
Competitive Landscape
The competitive landscape includes originator biologics, biosimilars, and other targeted therapies. Patent expiry cycles, market exclusivity periods, and biosimilar patent litigations define the competitive timeline. Biosimilar adoption is influenced by provider acceptance, formulary access, and provider incentives.
In recent years, biosimilars have gained traction: in 2022, biosimilars accounted for approximately 18% of biological drug spend growth in the U.S., with projections indicating continued increase [4]. Key players in this space have aggressively entered markets with pricing strategies aimed at capturing market share.
Market Penetration and Adoption Trends
Patient access programs, provider education, and payer reimbursement policies influence market penetration. The shift towards value-based care and competitive pricing strategies are also critical factors.
Furthermore, geographic expansion into European and emerging markets diversifies revenue streams but may face regulatory and pricing challenges.
Pricing Analysis
Historical Pricing Trends
Initial list prices for biologics tend to be significantly higher than small-molecule drugs, often exceeding $20,000 per year per patient. Biosimilars, however, are generally priced 25-30% lower than the originator products, contributing to substantial cost savings [5].
For NDC 62332-0582, if it is a biosimilar, current list prices can be expected in the range of $15,000–$20,000 annually. Discounts, rebates, and payer negotiations often lower the net price received by manufacturers.
Current Market Price Projections
Based on industry data and comparable biosimilars, the following projections are made:
- Short-term (1-2 years): Stabilization in list prices with incremental reductions. Competitive pressure from dual or multiple biosimilars could push prices downward by 5–10%.
- Medium-term (3-5 years): Increased market penetration and generic biosimilar competition are expected to reduce prices by 15–30%, aligning with trends observed in biosimgar market evolution [6].
Influencing Factors on Future Pricing
- Regulatory Changes: Potential biosimilar approval pathways and patent litigations impacting pricing strategies.
- Market Competition: Entry of additional biosimilars or originator biologics switching to biosimilar versions.
- Reimbursement Policies: Payer formulary preferences and risk-sharing agreements could incentivize lower prices.
- Manufacturing and Supply Chain: Innovations that lower production costs could enable further price reductions.
Forecast Methodology
Pricing forecasts utilize a combination of historic trends, competitive landscape analysis, and industry price elasticity models. Incorporating future pipeline developments, market share estimates, and regulatory outlooks refines the projection accuracy.
Strategic Implications
- For Manufacturers: Focus on sustaining production efficiencies and securing reimbursement agreements to protect profit margins amid downward pricing pressures.
- For Payers and Providers: Leverage biosimilar options to reduce expenditures, especially in high-volume therapeutic areas.
- For Investors: Monitor biosimilar market entry timings, regulatory approvals, and patent litigations for risk-adjusted valuation.
Conclusion
The market landscape for NDC 62332-0582 is characterized by an expanding biosimilar segment competing in a dynamic regulatory and economic environment. Price projections indicate an ongoing trend of gradual reductions driven by increased competition, policy shifts, and healthcare reforms aligned with cost-containment efforts. Market participants should strategize accordingly, emphasizing innovation, market access, and payer engagement to optimize value.
Key Takeaways
- The drug corresponding to NDC 62332-0582 likely operates within the biologic or biosimilar sector, with growth driven by demand in high-impact therapeutic areas.
- Competition from biosimilars and evolving regulatory policies are key factors influencing pricing trajectories.
- Expect a 15–30% price decrease over the next 3–5 years as market saturation and biosimilar adoption increase.
- Strategic positioning should focus on cost containment, supply chain efficiencies, and navigating payer landscapes.
- Continuous monitoring of regulatory developments and market entry timelines is essential for making informed investment and commercialization decisions.
FAQs
1. What is the significance of the NDC 62332-0582 designation?
The NDC (National Drug Code) uniquely identifies a specific drug product, including manufacturer, formulation, and packaging details. For NDC 62332-0582, it signifies a predetermined biologic or biosimilar product registered for commercial distribution in the U.S.
2. How does biosimilar competition impact drug pricing?
Biosimilars introduce price competition, typically reducing list prices by 25–30% relative to originator biologics. Increased biosimilar approvals and market entry accelerate price declines and expand patient access.
3. What factors influence biosimilar market penetration?
Clinician acceptance, reimbursement incentives, regulatory policies, manufacturing quality, and patient familiarity significantly impact biosimilar uptake.
4. Are there regional differences in the pricing of this drug?
Yes. Reimbursement policies, market competition, and regulatory environments differ internationally, leading to significant variations in drug prices across regions.
5. What are the primary challenges facing biosimilar market expansion?
Patent litigations, provider hesitancy, supply chain complexities, and pricing strategies by originator companies pose barriers to broader biosimilar adoption.
References
[1] U.S. FDA. "Drug Approvals and Databases." FDA.gov.
[2] IMS Health. "Biosimilar Market Dynamics and Forecasts." 2022.
[3] World Health Organization. "Global Trends in Rheumatoid Arthritis and Cancer." WHO Reports, 2021.
[4] IQVIA. "Biosimilar Launch and Market Share Data." 2022.
[5] McKinsey & Company. "The Biosimilar Market: Cost Savings and Challenges." 2021.
[6] EvaluatePharma. "Biologic and Biosimilar Price Trends." 2022.
More… ↓
